Last reviewed · How we verify
OnabotulinumtoxinA 100 UNT [Botox]
OnabotulinumtoxinA 100 UNT [Botox] is a Neurotoxin; botulinum toxin type A Small molecule drug developed by Women and Infants Hospital of Rhode Island. It is currently FDA-approved for Cervical dystonia, Blepharospasm, Strabismus. Also known as: Botox, Onabot/A.
OnabotulinumtoxinA blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
OnabotulinumtoxinA blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.
At a glance
| Generic name | OnabotulinumtoxinA 100 UNT [Botox] |
|---|---|
| Also known as | Botox, Onabot/A |
| Sponsor | Women and Infants Hospital of Rhode Island |
| Drug class | Neurotoxin; botulinum toxin type A |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Small molecule |
| Therapeutic area | Neurology; Dermatology; Aesthetics |
| Phase | FDA-approved |
Mechanism of action
The drug is a botulinum toxin serotype A that irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle release. This prevents neurotransmitter signaling at the neuromuscular junction, resulting in flaccid paralysis of targeted muscles. The effect is temporary, lasting 3–4 months, after which nerve terminals regenerate and muscle function returns.
Approved indications
- Cervical dystonia
- Blepharospasm
- Strabismus
- Chronic migraine
- Severe primary axillary hyperhidrosis
- Glabellar lines (aesthetic)
- Crow's feet (aesthetic)
- Forehead lines (aesthetic)
Common side effects
- Headache
- Neck pain
- Injection site pain
- Muscle weakness
- Eyelid ptosis
- Diplopia
- Flu-like syndrome
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OnabotulinumtoxinA 100 UNT [Botox] CI brief — competitive landscape report
- OnabotulinumtoxinA 100 UNT [Botox] updates RSS · CI watch RSS
- Women and Infants Hospital of Rhode Island portfolio CI
Frequently asked questions about OnabotulinumtoxinA 100 UNT [Botox]
What is OnabotulinumtoxinA 100 UNT [Botox]?
How does OnabotulinumtoxinA 100 UNT [Botox] work?
What is OnabotulinumtoxinA 100 UNT [Botox] used for?
Who makes OnabotulinumtoxinA 100 UNT [Botox]?
Is OnabotulinumtoxinA 100 UNT [Botox] also known as anything else?
What drug class is OnabotulinumtoxinA 100 UNT [Botox] in?
What development phase is OnabotulinumtoxinA 100 UNT [Botox] in?
What are the side effects of OnabotulinumtoxinA 100 UNT [Botox]?
What does OnabotulinumtoxinA 100 UNT [Botox] target?
Related
- Drug class: All Neurotoxin; botulinum toxin type A drugs
- Target: All drugs targeting SNAP-25 (synaptosome-associated protein of 25 kDa)
- Manufacturer: Women and Infants Hospital of Rhode Island — full pipeline
- Therapeutic area: All drugs in Neurology; Dermatology; Aesthetics
- Indication: Drugs for Cervical dystonia
- Indication: Drugs for Blepharospasm
- Indication: Drugs for Strabismus
- Also known as: Botox, Onabot/A
- Compare: OnabotulinumtoxinA 100 UNT [Botox] vs similar drugs
- Pricing: OnabotulinumtoxinA 100 UNT [Botox] cost, discount & access